Akari Therapeutics plc has entered into a partnership with WuXi XDC to advance the manufacturing of its lead antibody drug conjugate $(ADC)$, AKTX-101. This collaboration aims to produce GMP-grade clinical product to support upcoming Phase 1 clinical trials, planned for late 2026 or early 2027, pending regulatory clearance. WuXi XDC, recognized as a global leader in ADC development and manufacturing, will play a key role in helping Akari transition from a preclinical discovery company to a clinical-stage biotechnology player.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9617854-en) on December 30, 2025, and is solely responsible for the information contained therein.